Most preclinical pharmacology studies in MASH and hepatic fibrosis have focused on fibrillar collagens (type I and type III) but have overlooked the basement membrane ECM, which is comprised of type IV collagen, laminin, nidogen, and sulfated proteoglycans. The gene discussed is LAMB2; the disease is Hepatic fibrosis.